Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Glaxo Wellcome evaluates new alpha1a-adrenoceptor antagonist

Dec. 13, 1996

Biogen, Creative BioMolecules to codevelop drugs for renal disorders

Dec. 12, 1996

cGMP-PDE inhibitors revealed by Fujisawa

Dec. 11, 1996

P&U anticipates filing for urinary incontinence treatment soon

Dec. 10, 1996

Merck & Co. reveals new agents for BPH

Dec. 10, 1996

VIP analogs and derivatives claimed for smooth muscle relaxation

Dec. 9, 1996

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Dec. 6, 1996

Synsorb Pk licensed to major Japanese pharmaceutical company

Dec. 4, 1996

Chugai starts phase I clinical trials with phosphate binder

Dec. 4, 1996

Negative clinical results reported for aromatase inhibitor in BPH

Nov. 29, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...